Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
WALTHAM, Mass., Aug. 31, 2016 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that John V. Oyler, Founder, Chief Executive Officer, and Chairman, and Howard Liang, Ph.D., Chief Financial Officer and Chief Strategy Officer, will present at the following two upcoming investor conferences in New York City, NY:
Baird 2016 Global Healthcare Conference
Date: Wednesday, September 7, 2016
Time: 10:15 a.m. ET
Morgan Stanley 2016 Global Healthcare Conference
Date: Monday, September 12, 2016
Time: 11:05 a.m. ET
Live webcasts of the presentations can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. Archived replays will be available for 90 days following the conferences.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 250 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Media/Investor Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
